Celgene to buy Impact Biomedicines for up to $7 billion; Pfizer plans to cut 300 positions in neuroscience; Perrigo hires new CEO
Denise Strauss, formerly VP of cardiovascular marketing at Boehringer Ingelheim, will oversee the drugmaker's marketing activities.
The neurology market is again attracting attention and investment from various — and at times unexpected — corners of the biopharma industry.
MS drugs top the list, led by Teva's Copaxone, Biogen's Tecfida and Avonex, and Novartis' Gilenya.
The experimental therapy is positioned to fill a market gap in primary progressive multiple sclerosis.
Millian, a former Sanofi and Merck executive, on marketing new therapies in the MS market.